Skip to content

Microdosing: all studies

Page 38 of 56: studies 371 to 380 of 555, newest first. Back to the microdosing overview

Research

Altered States, Enhanced Potential: Psychedelics and Physical Performance

June 12, 2026 Zane Qarni, Jérémie Richard preprint

Interest in psychedelics has expanded beyond clinical treatment contexts, yet little empirical work has examined how users describe psychedelic use in relation to sport and physical activity. This study conducted a qualitative content analysis of Reddit discussions involving psychedelics and physical performance. A Reddit search for “sports psychedelics” returned 253 threads. After screening,...

DOI: 10.31234/osf.io/txgq2_v2 (opens in new tab) Psilocybin Perception Cognition Empirical research +9

Métodos experimentales en psicoanálisis: Reflexiones epistemológicas sobre sustancias psicoactivas y el inconsciente

MINKA Revista de la Federación Iberoamericana de Psicodélicos y Enteógenos June 10, 2026 Liber Rodríguez

Este artículo revisa la cuestión epistemológica del uso de métodos experimentales en psicoanálisis, focalizando en el empleo de sustancias psicoactivas como vía de acceso y exploración del inconsciente. A partir de una relectura crítica de antecedentes históricos —desde Moreau de Tours y Freud hasta experiencias contemporáneas con LSD y hongos psilocibios— se analiza cómo estas prácticas...

Patient perceptions towards psychedelics for musculoskeletal pain: A cross-sectional survey

medRxiv June 1, 2026 Erica J. Li, Basmah Mosharraf, Hiba Ali et al. preprint

Background: Psychedelics are emerging as potential management options for chronic musculoskeletal pain due to preliminary evidence of effectiveness and low addictive potential, but patients’ perceptions remain unknown. This study assessed patient perceptions regarding psilocybin for musculoskeletal pain. Methods: We conducted a cross-sectional survey of adults (≥19) with musculoskeletal pain...

Classic psychedelics and personality: An updated systematic review.

Journal of Psychopharmacology May 31, 2026 Anna Beatriz Vicentini, Caio César De Paula, José Augusto Silva Reis et al.

The impact of classic psychedelics (5-HT2A receptor agonists) on personality traits has been studied for decades, and it has been hypothesized that the mechanisms underlying these changes are linked to agonism at cortical serotonergic 5-HT2A receptors. However, research results are contradictory. Therefore, the present paper aims to systematically evaluate the effects of psychedelics on...

DOI: 10.1177/02698811261449386 (opens in new tab) Full text (opens in new tab) 5-ht2a receptor agonists Classic psychedelics Personality traits Systematic review

From monotherapy to sequential models: An updated scoping review on ibogaine’s role in treatment for psychiatric disorders

Journal of Psychopharmacology May 12, 2026 Pravesh Sharma, Jared Kendrick, Jennifer Schram et al.

BACKGROUND: Preliminary evidence examining ibogaine in neuropsychiatric and substance use disorders is accumulating. As patient interest and off-label use grow, clinicians require an understanding of emerging dosing strategies, investigational protocols, and reported adverse effects to appropriately counsel patients and contextualize potential risks and benefits. METHODS: Databases were...

DOI: 10.1177/02698811261443674 (opens in new tab) Observational study Adverse effect Dosing Randomized controlled trial +10

Electrocorticographic Changes and Neuronal Maturation in the Antidepressant-like and Anxiolytic Effects of Micro- or Macrodosing of Psilocybe cubensis Mushroom in Mice

Molecules April 18, 2026 Flor Eréndira Sánchez-cortés, Nelly Maritza Vega-Rivera, Raúl Iván Escamilla-Orozco et al.

Mushroom use dates back to ancient times, and it currently remains significant among indigenous and urban populations as a medicinal option. Psilocybe species are suggested to modify emotions when administered in macro- or microdose form for the treatment of anxiety and depression, both often affected by a delayed onset and adverse effects of current pharmacological therapy. The objective of...

DOI: 10.3390/molecules31081331 (opens in new tab) Anxiolytic Fluoxetine Hippocampus Corticosterone +5

The Use of Psychedelics in the Treatment of Adult ADHD: A Systematic and Mechanistic Review.

International Journal of Molecular Sciences April 12, 2026 James Chmiel, Agnieszka Malinowska, Donata Kurpas

Interest in classical psychedelics as potential treatments for ADHD has grown alongside broader psychiatric psychedelic research, but ADHD-specific evidence remains limited. This systematic review examined prospective and experimental studies on whether classical psychedelics, including microdosing-like use and retreat-based exposure, are associated with changes in adult ADHD symptoms and...

DOI: 10.3390/ijms27083453 (opens in new tab) Full text (opens in new tab) ADHD Neurodevelopmental disorders Pharmacotherapy Psychedelics

Severe Illness Associated with Eating Mushroom-Containing Chocolate Products — United States, January–October 2024

MMWR Morbidity and Mortality Weekly Report April 9, 2026 Jelonia T. Rumph, Andrea Winquist, Alyssa N. Troeschel et al.

In late spring 2024, CDC was alerted to an outbreak of poisoning potentially associated with eating Diamond Shruumz microdosing chocolate bars. Diamond Shruumz microdosing chocolate bars are edible products designed so that small doses of mushroom-derived psychoactive compounds and other psychoactive ingredients can be eaten in a presectioned serving. In response to this alert, CDC and the Food...

Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution

Canadian Journal of Public Health March 19, 2026 Jenna Matsukubo, Erik Loewen Friesen, Rachael MacDonald-Spracklin et al. 1 citation

IntroductionThe use of psychedelics has increased in Canada in recent years. Although non-medical psilocybin use is prohibited under the Controlled Drugs and Substances Act, we previously documented the emergence of grey-market brick-and-mortar psilocybin retailers. This study examined changes in the number, composition, and geographic distribution of Canadian psilocybin retail stores between...

m-DASC: Measuring Subjective Effects of Very Low Doses of Psychedelic Drugs.

Psychedelic Medicine March 1, 2026 Jonah Griffin-Stolbach, Hanna Molla, Donald Hedeker et al.

There has been great interest in the use of very low doses of psychedelic drugs like lysergic acid diethylamide (LSD) to improve mood and cognition. However, controlled studies have thus far provided little support for their efficacy. One challenge is that the subjective effects are subtle and on the threshold of detectability, whereas the questionnaires used to assess the drugs' effects were...